HDAC inhibitors, including the class I-selective SK-7041, significantly reduced cardiac hypertrophy induced by Ang II or aortic banding and improved survival in mice.
Does HDAC inhibition prevent or reverse cardiac hypertrophy induced by Angiotensin II or aortic banding in mice and rats?
HDAC inhibition, primarily mediated by class I HDACs, prevents and partially reverses cardiac hypertrophy in response to agonist and stretch stimuli in animal models.
BACKGROUND: A number of distinct stress signaling pathways in myocardium cause cardiac hypertrophy and heart failure. Class II histone deacetylases (HDACs) antagonize several stress-induced pathways and hypertrophy. However, cardiac hypertrophy induced by transgenic overexpression of the homeodomain only protein, HOP, can be prevented by the nonspecific HDAC inhibitors trichostatin A and valproic acid, suggesting that alternate targets that oppose class II HDAC function might exist in myocardium. We tested the effects of several HDAC inhibitors, including a class I HDAC-selective inhibitor, SK-7041, on cardiac hypertrophy induced by angiotensin II (Ang II) treatment or aortic banding (AB). METHODS AND RESULTS: Cardiac hypertrophy was induced by chronic infusion of Ang II or by AB in mice or rats and evaluated by determining the ratio of heart weight to body weight or to tibia length, cross-sectional area, or echocardiogram. Cardiac hypertrophy induced by Ang II or AB for 2 weeks was significantly reduced by simultaneous administration of trichostatin A, valproic acid, or SK-7041. Echocardiogram revealed that exaggerated left ventricular systolic dimensions were relieved by HDAC inhibitors. HDAC inhibitors partially reversed preestablished cardiac hypertrophy and improved survival of AB mice. The expressions of atrial natriuretic factor, alpha-tubulin, beta-myosin heavy chain, and interstitial fibrosis were reduced by HDAC inhibition. CONCLUSIONS: These results suggest that the predominant effect of HDAC inhibition, mainly mediated by class I HDACs, is to prevent cardiac hypertrophy in response to a broad range of agonist and stretch stimuli.
Kee et al. (Wed,) conducted a other in Cardiac hypertrophy. HDAC inhibitors (trichostatin A, valproic acid, or SK-7041) was evaluated on Cardiac hypertrophy (ratio of heart weight to body weight or to tibia length, cross-sectional area, or echocardiogram). HDAC inhibitors, including the class I-selective SK-7041, significantly reduced cardiac hypertrophy induced by Ang II or aortic banding and improved survival in mice.